180 related articles for article (PubMed ID: 17335313)
1. Cost-effectiveness measures, methods, and policy implications from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for schizophrenia.
Rosenheck RA; Lieberman JA
J Clin Psychiatry; 2007 Feb; 68(2):e05. PubMed ID: 17335313
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials.
Lieberman JA
J Clin Psychiatry; 2007 Feb; 68(2):e04. PubMed ID: 17335312
[TBL] [Abstract][Full Text] [Related]
3. Second-generation antipsychotics: cost-effectiveness, policy options, and political decision making.
Rosenheck RA; Leslie DL; Doshi JA
Psychiatr Serv; 2008 May; 59(5):515-20. PubMed ID: 18451007
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
5. NAMI perspective on CATIE: policy and research implications.
Duckworth K; Fitzpatrick MJ
Psychiatr Serv; 2008 May; 59(5):537-9. PubMed ID: 18451013
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial-based cost-effectiveness analyses of antipsychotic use.
Polsky D; Doshi JA; Bauer MS; Glick HA
Am J Psychiatry; 2006 Dec; 163(12):2047-56. PubMed ID: 17151153
[TBL] [Abstract][Full Text] [Related]
7. What do large scale studies of medication in schizophrenia add to our management strategies?
Agius M; Davis A; Gilhooley M; Chapman S; Zaman R
Psychiatr Danub; 2010 Jun; 22(2):323-8. PubMed ID: 20562774
[TBL] [Abstract][Full Text] [Related]
8. Assessing the value of antipsychotics for treating schizophrenia: the importance of evaluating and interpreting the clinical significance of individual service costs.
Tunis SL; Ascher-Svanum H; Stensland M; Kinon BJ
Pharmacoeconomics; 2004; 22(1):1-8. PubMed ID: 14720078
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making.
Foussias G; Remington G
Can J Psychiatry; 2010 Mar; 55(3):117-25. PubMed ID: 20370961
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia.
Park T; Kuntz KM
Value Health; 2014 Jun; 17(4):310-9. PubMed ID: 24968989
[TBL] [Abstract][Full Text] [Related]
11. Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: implications for schizophrenia treatment.
Neumann PJ
J Clin Psychiatry; 1999; 60 Suppl 3():9-14; discussion 15. PubMed ID: 10073371
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.
Tunis SL; Faries DE; Nyhuis AW; Kinon BJ; Ascher-Svanum H; Aquila R
Value Health; 2006; 9(2):77-89. PubMed ID: 16626411
[TBL] [Abstract][Full Text] [Related]
13. The NIMH-CATIE Schizophrenia Study: what did we learn?
Lieberman JA; Stroup TS
Am J Psychiatry; 2011 Aug; 168(8):770-5. PubMed ID: 21813492
[No Abstract] [Full Text] [Related]
14. Tying comparative effectiveness information to decision-making and the future of comparative effectiveness research designs: the case for antipsychotic drugs.
Basu A; Meltzer HY
J Comp Eff Res; 2012 Mar; 1(2):171-80. PubMed ID: 24237376
[TBL] [Abstract][Full Text] [Related]
15. Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies.
Davis SM; Koch GG; Davis CE; LaVange LM
Schizophr Bull; 2003; 29(1):73-80. PubMed ID: 12908662
[TBL] [Abstract][Full Text] [Related]
16. [Expensive but nevertheless cost effect? Pharmacoeconomics of atypical neuroleptics].
Laux G; Günther W
Pharm Unserer Zeit; 2002; 31(6):572-6. PubMed ID: 12481515
[No Abstract] [Full Text] [Related]
17. Perspective and the measurement of costs and benefits for cost-effectiveness analysis in schizophrenia.
Meltzer D
J Clin Psychiatry; 1999; 60 Suppl 3():32-5; discussion 36-7. PubMed ID: 10073375
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE).
Lieberman JA
Arch Gen Psychiatry; 2006 Oct; 63(10):1069-72. PubMed ID: 17015808
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
Rajagopalan K; Hassan M; O'Day K; Meyer K; Grossman F
J Med Econ; 2013 Jul; 16(7):951-61. PubMed ID: 23701260
[TBL] [Abstract][Full Text] [Related]
20. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
